Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Recurring seizures a common challenge for brain cancer patients, including me. So grateful to Dr Helen Wheeler my excellent neuro-oncologist for her expertise in managing the anti-seizure meds! Here’s an update from my perspective.

Professor Richard Scolyer AO

22,690 subscribers

39,175 views • 2 years ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

“Most of the people I’ve seen with #MECFS are so much sicker than my cancer patients.” Dr. Fridbjörn Sigurdsson, a former medical oncologist now focused on ME/CFS, speaking at the 2025 @Invest_in_me conference. Thanks to ME/CFS Science for finding the clip.

“Most of the people I’ve seen with #MECFS are so much sicker than my cancer patients.” Dr. Fridbjörn Sigurdsson, a former medical oncologist now focused on ME/CFS, speaking at the 2025 @Invest_in_me conference. Thanks to ME/CFS Science for finding the clip.

Adam

60,956 views • 10 months ago

Just received my appointment for 7am on Dec 12 from my ONCOLOGIST for December 12 for bloodwork & my full body PET SCAN which will determine if I am cancer free. Yes it is a major concern as only cancer patients know the anxiety involved in getting the call with the findings.

Just received my appointment for 7am on Dec 12 from my ONCOLOGIST for December 12 for bloodwork & my full body PET SCAN which will determine if I am cancer free. Yes it is a major concern as only cancer patients know the anxiety involved in getting the call with the findings.

Dick Vitale

670,113 views • 1 year ago

Glad to be able to talk about ovarian cancer, which I’m managing for the third time, with my oncologist, Dr. Angela George, from the Royal Marsden NHS Foundation Trust. We discuss the importance of listening to our bodies, advances in treatment, and living with what can be a permanent condition. Thanks to Hannah Vaughan Jones for hosting us on Changing the Ovarian Cancer Story. @OvCancerDay

Glad to be able to talk about ovarian cancer, which I’m managing for the third time, with my oncologist, Dr. Angela George, from the Royal Marsden NHS Foundation Trust. We discuss the importance of listening to our bodies, advances in treatment, and living with what can be a permanent condition. Thanks to Hannah Vaughan Jones for hosting us on Changing the Ovarian Cancer Story. @OvCancerDay

Christiane Amanpour

46,997 views • 9 months ago

Tammy is a true leader for Illinois who doesn’t back down from a challenge. I'm so grateful to have her endorsement in my campaign for United States Senate.

Tammy is a true leader for Illinois who doesn’t back down from a challenge. I'm so grateful to have her endorsement in my campaign for United States Senate.

Juliana Stratton

227,212 views • 1 year ago

A man approached me after our event in Strongsville to convey that he was benefiting from the drug my company developed for prostate cancer. So grateful. Let’s pray for his health & continued recovery. 🙏

A man approached me after our event in Strongsville to convey that he was benefiting from the drug my company developed for prostate cancer. So grateful. Let’s pray for his health & continued recovery. 🙏

Vivek Ramaswamy

166,400 views • 22 days ago

Here’s a video from last night that my son shot of the delivery at Tesla for my Signature #217. Extremely grateful to the Mechanicsburg, PA staff for an amazing delivery experience. ❤️

Here’s a video from last night that my son shot of the delivery at Tesla for my Signature #217. Extremely grateful to the Mechanicsburg, PA staff for an amazing delivery experience. ❤️

Michael Rauch

11,039 views • 1 month ago

In 1996, Dr. Linda Peeno admitted to refusing a man a life-saving procedure—effectively causing his death—in order to save her employer $500,000, which secured her "continued advancement in the healthcare field... to an escalating six figure income". "In all my work, I had one primary duty, and that was to use my medical expertise for the financial benefit of the organisation for which I worked." "What kind of system have we created when a physician can receive a lucrative income for adding to the suffering of patients?" "I became a physician to care for and not bring harm to my patients."

In 1996, Dr. Linda Peeno admitted to refusing a man a life-saving procedure—effectively causing his death—in order to save her employer $500,000, which secured her "continued advancement in the healthcare field... to an escalating six figure income". "In all my work, I had one primary duty, and that was to use my medical expertise for the financial benefit of the organisation for which I worked." "What kind of system have we created when a physician can receive a lucrative income for adding to the suffering of patients?" "I became a physician to care for and not bring harm to my patients."

healthbot

217,587 views • 7 months ago

Dr. William Makis exposes a monumental hypocrisy in the cancer world. Fenbendazole is dismissed as a "dog dewormer," while its near-identical human counterpart, Mebendazole, is a recognized human antiparasitic. But there's a catch. Johns Hopkins, an institution central to the COVID-19 narrative, holds a patent on Mebendazole for cancer—specifically for brain cancers. Seeing this, Dr. Makis began advising terminal patients to try repurposed antiparasitics like Ivermectin and Fenbendazole. The results were not just promising; they were miraculous. Stage four cancer patients started returning with unbelievable news: "My tumors are shrinking." "My oncologist told me I should be dead." "I'm alive because of you." Their stories are a testament to the life-saving potential of these demonized drugs. While institutions play games with patents and narratives, real people are getting their lives back.

Dr. William Makis exposes a monumental hypocrisy in the cancer world. Fenbendazole is dismissed as a "dog dewormer," while its near-identical human counterpart, Mebendazole, is a recognized human antiparasitic. But there's a catch. Johns Hopkins, an institution central to the COVID-19 narrative, holds a patent on Mebendazole for cancer—specifically for brain cancers. Seeing this, Dr. Makis began advising terminal patients to try repurposed antiparasitics like Ivermectin and Fenbendazole. The results were not just promising; they were miraculous. Stage four cancer patients started returning with unbelievable news: "My tumors are shrinking." "My oncologist told me I should be dead." "I'm alive because of you." Their stories are a testament to the life-saving potential of these demonized drugs. While institutions play games with patents and narratives, real people are getting their lives back.

Camus

238,737 views • 9 months ago

IMPORTANT UPDATE! There is a request for an arrest warrant against me in Norway. Here’s my response >>

IMPORTANT UPDATE! There is a request for an arrest warrant against me in Norway. Here’s my response >>

Hananya Naftali

110,139 views • 1 year ago

Speaking from experience there is no awareness of anything being said to a person during a Tonic-clonic (grand mal) seizure. It’s not me in the video but this is what my life has been for over 5 years now. This year on Mother’s Day all 4 of my kids watched this happen to me in our kitchen. It was the first time they’d all seen my grand mal seizures. Up until the past few months they’ve usually occurred in my sleep. My children haven’t looked at me the same since. My seizures have become alarmingly frequent since the new year. An average of 2 or 3 grand mal seizures per week. So I recently took a long break from X to see if removing the stress would help. I also started a new medication. But as of last night it’s clear that neither will be an instant fix. I’m posting this to ask that you please pray for my family.🙏❤️‍🔥

Sensitive content

Speaking from experience there is no awareness of anything being said to a person during a Tonic-clonic (grand mal) seizure. It’s not me in the video but this is what my life has been for over 5 years now. This year on Mother’s Day all 4 of my kids watched this happen to me in our kitchen. It was the first time they’d all seen my grand mal seizures. Up until the past few months they’ve usually occurred in my sleep. My children haven’t looked at me the same since. My seizures have become alarmingly frequent since the new year. An average of 2 or 3 grand mal seizures per week. So I recently took a long break from X to see if removing the stress would help. I also started a new medication. But as of last night it’s clear that neither will be an instant fix. I’m posting this to ask that you please pray for my family.🙏❤️‍🔥

sᥕᥱᥱ𝗍 𝗍һіᥒg❤️‍🔥(𝙰𝚜𝚒𝚊)

1,192,629 views • 2 months ago

My tee shot today on par 3 14th at Laurel Valley to support the GREAT Dr Stanley Marks and his cancer research which has improved the quality of life for so many cancer patients. I missed the birdie putt 😳

My tee shot today on par 3 14th at Laurel Valley to support the GREAT Dr Stanley Marks and his cancer research which has improved the quality of life for so many cancer patients. I missed the birdie putt 😳

Bob Pompeani

49,959 views • 1 year ago

“I studied 16-17 hours a day, worked very hard for this. I gave my best. It seems like a dream now. I lost my grandmother to cancer which inspired me to become an Oncologist.” - NEET-UG AIR 1 Aryan Gupta

“I studied 16-17 hours a day, worked very hard for this. I gave my best. It seems like a dream now. I lost my grandmother to cancer which inspired me to become an Oncologist.” - NEET-UG AIR 1 Aryan Gupta

News Arena India

166,716 views • 27 days ago

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." This clip of Dr. Makis (William Makis), a radiologist, oncologist, and cancer researcher, is taken from an interview with Seth Holehouse () posted to Rumble on November 21, 2025. ----------------Partial transcription of clip--------------- "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases."

Sense Receptor

228,297 views • 8 months ago

I matched at my #1 …Georgetown/ MedStar for my anesthesiology residency! I’m so grateful to all of my friends and family and teachers for supporting me throughout my whole life and throughout this journey!!!! My future patients- this is for you!! 🩺 #Match2024 Women in Anesthesiology

I matched at my #1 …Georgetown/ MedStar for my anesthesiology residency! I’m so grateful to all of my friends and family and teachers for supporting me throughout my whole life and throughout this journey!!!! My future patients- this is for you!! 🩺 #Match2024 Women in Anesthesiology

Helena Lysandrou

18,539 views • 2 years ago

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

A Cancer Breakthrough That Changes Everything In a stunning medical advance, Dr. Patrick Soon-Shiong reveals a platform technology achieving near-complete responses in patients with terminal cancers—including brain, pancreatic, and head & neck tumors—after all other treatments failed. This isn't a traditional chemo or radiation. It's a dual approach that empowers the body's own immune system. Here’s the revolutionary breakdown: 1. The "BioShield" Injection: The key is a stabilized form of IL-15 (Interleukin-15), a protein that acts as "food" for your Natural Killer (NK) cells. The NIH tried for a decade to develop IL-15 but failed because it naturally lasts only 2 minutes in the body. Dr. Soon-Shiong's team engineered it to last for 7 days with a simple 5-minute subcutaneous injection, continuously proliferating the patient's NK cells. 2. The Combined Infusion: Patients receive this "BioShield" injection along with an infusion of powerful NK cells, creating a targeted army to attack the cancer. The Proven Results: - Metastatic Pancreatic Cancer: Patients alive 6 years later. - Merkel Cell Carcinoma: Patients surviving 9 years. - Bladder Cancer: Approved by the FDA in April 2024, with patients disease-free for 10 years. - Lung Cancer: In new trials, the therapy has tripled survival for patients who failed everything, including chemo and checkpoint inhibitors. The therapy is also being used preemptively. The NCI has designated it for a trial on patients with Lynch syndrome (1 in 280 Americans), who have an 80% higher risk of cancers, to provide a "Cancer BioShield." The data is based on experience with over 8,000 patients. The challenge now is regulatory. Despite its pan-tumor potential, the current system requires a separate 10-year, 700,000-page approval process for each cancer type. This is a paradigm shift. We don't ask what kind of anemia you have before a blood transfusion. The body needs NK cells and T-cells to fight cancer, regardless of the tumor type.

Camus

421,950 views • 10 months ago

“Grateful to have shared my music at the African Leadership Network’s inspiring gathering in Kigali. It was an honor to perform for a group so dedicated to nurturing Africa’s future leaders. Here’s a glimpse from the night where melodies met the spirit of transformation. #ALN2023

“Grateful to have shared my music at the African Leadership Network’s inspiring gathering in Kigali. It was an honor to perform for a group so dedicated to nurturing Africa’s future leaders. Here’s a glimpse from the night where melodies met the spirit of transformation. #ALN2023

Bruce Melodie

31,192 views • 2 years ago

TODAY: The Daily Mail published an interview with me about my felony charges for saving beagles from Ridglan Farms. I'm grateful for the coverage. Let's keep on building momentum to save the pups — including the 15,000+ stuck in labs at MBR in New York.

TODAY: The Daily Mail published an interview with me about my felony charges for saving beagles from Ridglan Farms. I'm grateful for the coverage. Let's keep on building momentum to save the pups — including the 15,000+ stuck in labs at MBR in New York.

Dean Guzman Wyrzykowski

13,934 views • 2 months ago

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Oncologist Dr. William Makis: "Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer...[and is] running, quietly, several clinical trials with mebendazole in cancer...So this is not fringe... There's... real science behind it, patents behind it." "For the past year and a half, I've been working with antiparasitics that are being repurposed for cancer. This is ivermectin, mebendazole and fenbendazole. And the reason is because there's a big body of research. There are over 400 published papers on ivermectin in cancer. There are over 240 published papers on mebendazole in cancer. "In fact, Johns Hopkins quietly secured a patent in 2021 on mebendazole for treatment in cancer, specifically the most aggressive cancer, which is glioblastoma, brain cancer, extremely aggressive cancer. Johns Hopkins has the patent. They are also running quietly several clinical trials with mebendazole in cancer. There's colon cancer, gastric cancer and brain cancer, including children, children with brain cancers as well. So this is not fringe, this is not, something that is far out. There's actually real science behind it, patents behind it. Dr. Sulack Pete "And when you search a lot of the AIs, for example Perplexity AI and you ask what are the most promising repurposed drugs for terminally ill cancer patients today, it will give you in its search, in the top three, you will get ivermectin as number one, mebendazole and fenbendazole, there's other antiparasitics like hydroxychloroquine will be in the top 10, you will have curcumin in the top 10, you will have EGCG, which is from green tea extract in the top 10, resveratrol in the top 10, metformin, which is a diabetes drug but also has anti-cancer activity in the top 10 as well. "And what I have found working with these antiparasitics, is that there is a benefit to patients in at least 75% of the cases." Follow me for more Bombshell. #Fenbendazole #Ivermectin #Cancercure

Dr. Zakaria MD

46,717 views • 1 month ago